Merck and Moderna announced in August that adding their mRNA cancer vaccine to an existing treatment slowed the return and spread of melanoma, according to STAT. The late-stage result was eagerly awaited, with Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, saying the field had been waiting "with bated breath" for the news on the drug, called intismeran autogene.
The outcome suggests that using messenger RNA to train the immune system against cancer — an idea first developed decades ago — is ready for further drug development. But the STAT report, titled "Divergent trial results on cancer vaccines," notes that the field is still grappling with hard questions. The excerpt highlights the melanoma success but does not detail the divergent results, leaving open which other cancers might respond.
Researchers remain excited about the approach, yet much is unknown. The key challenge now is determining which tumor types mRNA vaccines can be harnessed against, and whether the technology will prove broadly effective beyond melanoma. The source does not provide comparative data from other trials, so the full picture of divergent outcomes is not yet clear from this report alone.